Clinical spectrum of rare bone fragility disorders and response to bisphosphonate treatment: a retrospective study
Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous group of diseases characterized by brittle bones. Though genetic mutations in COL1A1 and COL1A2 account for approximately 85–90% of OI cases, there are now more than twenty genes described, responsible for rare forms of OI. T...
Saved in:
Published in | European journal of human genetics : EJHG Vol. 32; no. 12; pp. 1559 - 1566 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.12.2024
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous group of diseases characterized by brittle bones. Though genetic mutations in
COL1A1
and
COL1A2
account for approximately 85–90% of OI cases, there are now more than twenty genes described, responsible for rare forms of OI. Treatment is based on the use of bisphosphonates and though it is well established that they increase lumbar spine (LS) bone mineral density (BMD), the clinical impact on fracture reduction is still debated.
In this study, we investigated the clinical characteristics of 38 patients with a bone fragility disorder that had variants in non-
COL1A1/COL1A2
genes in order to study genotype-phenotype correlations, as the natural history of these rare forms is still not well known. We then studied the usefulness of bisphosphonate treatment by evaluating the effects on LS BMD, annual non-vertebral fracture rate, bone turnover markers and height. This study enabled us to better define the natural history of patients with non-
COL1
pathogenic variants. Patients with
CRTAP
and
TMEM38B
variants consistently had a prenatal presentation with a short (<3
rd
p) and bowed femur. Importantly, this prenatal involvement does not predict the postnatal severity of the disease. Regarding treatment by bisphosphonates, all patients showed a significant increase in LS BMD while treated and this increase was dependent on the dose received. The increase in LS BMD also translated in a reduction of fracture rate during treatment. Finally, our study showed that the earlier bisphosphonates are initiated, the greater the fracture rate is reduced. |
---|---|
AbstractList | Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous group of diseases characterized by brittle bones. Though genetic mutations in COL1A1 and COL1A2 account for approximately 85-90% of OI cases, there are now more than twenty genes described, responsible for rare forms of OI. Treatment is based on the use of bisphosphonates and though it is well established that they increase lumbar spine (LS) bone mineral density (BMD), the clinical impact on fracture reduction is still debated.In this study, we investigated the clinical characteristics of 38 patients with a bone fragility disorder that had variants in non-COL1A1/COL1A2 genes in order to study genotype-phenotype correlations, as the natural history of these rare forms is still not well known. We then studied the usefulness of bisphosphonate treatment by evaluating the effects on LS BMD, annual non-vertebral fracture rate, bone turnover markers and height. This study enabled us to better define the natural history of patients with non-COL1 pathogenic variants. Patients with CRTAP and TMEM38B variants consistently had a prenatal presentation with a short (<3rd p) and bowed femur. Importantly, this prenatal involvement does not predict the postnatal severity of the disease. Regarding treatment by bisphosphonates, all patients showed a significant increase in LS BMD while treated and this increase was dependent on the dose received. The increase in LS BMD also translated in a reduction of fracture rate during treatment. Finally, our study showed that the earlier bisphosphonates are initiated, the greater the fracture rate is reduced.Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous group of diseases characterized by brittle bones. Though genetic mutations in COL1A1 and COL1A2 account for approximately 85-90% of OI cases, there are now more than twenty genes described, responsible for rare forms of OI. Treatment is based on the use of bisphosphonates and though it is well established that they increase lumbar spine (LS) bone mineral density (BMD), the clinical impact on fracture reduction is still debated.In this study, we investigated the clinical characteristics of 38 patients with a bone fragility disorder that had variants in non-COL1A1/COL1A2 genes in order to study genotype-phenotype correlations, as the natural history of these rare forms is still not well known. We then studied the usefulness of bisphosphonate treatment by evaluating the effects on LS BMD, annual non-vertebral fracture rate, bone turnover markers and height. This study enabled us to better define the natural history of patients with non-COL1 pathogenic variants. Patients with CRTAP and TMEM38B variants consistently had a prenatal presentation with a short (<3rd p) and bowed femur. Importantly, this prenatal involvement does not predict the postnatal severity of the disease. Regarding treatment by bisphosphonates, all patients showed a significant increase in LS BMD while treated and this increase was dependent on the dose received. The increase in LS BMD also translated in a reduction of fracture rate during treatment. Finally, our study showed that the earlier bisphosphonates are initiated, the greater the fracture rate is reduced. Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous group of diseases characterized by brittle bones. Though genetic mutations in COL1A1 and COL1A2 account for approximately 85–90% of OI cases, there are now more than twenty genes described, responsible for rare forms of OI. Treatment is based on the use of bisphosphonates and though it is well established that they increase lumbar spine (LS) bone mineral density (BMD), the clinical impact on fracture reduction is still debated. In this study, we investigated the clinical characteristics of 38 patients with a bone fragility disorder that had variants in non- COL1A1/COL1A2 genes in order to study genotype-phenotype correlations, as the natural history of these rare forms is still not well known. We then studied the usefulness of bisphosphonate treatment by evaluating the effects on LS BMD, annual non-vertebral fracture rate, bone turnover markers and height. This study enabled us to better define the natural history of patients with non- COL1 pathogenic variants. Patients with CRTAP and TMEM38B variants consistently had a prenatal presentation with a short (<3 rd p) and bowed femur. Importantly, this prenatal involvement does not predict the postnatal severity of the disease. Regarding treatment by bisphosphonates, all patients showed a significant increase in LS BMD while treated and this increase was dependent on the dose received. The increase in LS BMD also translated in a reduction of fracture rate during treatment. Finally, our study showed that the earlier bisphosphonates are initiated, the greater the fracture rate is reduced. Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous group of diseases characterized by brittle bones. Though genetic mutations in COL1A1 and COL1A2 account for approximately 85-90% of OI cases, there are now more than twenty genes described, responsible for rare forms of OI. Treatment is based on the use of bisphosphonates and though it is well established that they increase lumbar spine (LS) bone mineral density (BMD), the clinical impact on fracture reduction is still debated.In this study, we investigated the clinical characteristics of 38 patients with a bone fragility disorder that had variants in non-COL1A1/COL1A2 genes in order to study genotype-phenotype correlations, as the natural history of these rare forms is still not well known. We then studied the usefulness of bisphosphonate treatment by evaluating the effects on LS BMD, annual non-vertebral fracture rate, bone turnover markers and height. This study enabled us to better define the natural history of patients with non-COL1 pathogenic variants. Patients with CRTAP and TMEM38B variants consistently had a prenatal presentation with a short (<3 p) and bowed femur. Importantly, this prenatal involvement does not predict the postnatal severity of the disease. Regarding treatment by bisphosphonates, all patients showed a significant increase in LS BMD while treated and this increase was dependent on the dose received. The increase in LS BMD also translated in a reduction of fracture rate during treatment. Finally, our study showed that the earlier bisphosphonates are initiated, the greater the fracture rate is reduced. Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous group of diseases characterized by brittle bones. Though genetic mutations in COL1A1 and COL1A2 account for approximately 85–90% of OI cases, there are now more than twenty genes described, responsible for rare forms of OI. Treatment is based on the use of bisphosphonates and though it is well established that they increase lumbar spine (LS) bone mineral density (BMD), the clinical impact on fracture reduction is still debated.In this study, we investigated the clinical characteristics of 38 patients with a bone fragility disorder that had variants in non-COL1A1/COL1A2 genes in order to study genotype-phenotype correlations, as the natural history of these rare forms is still not well known. We then studied the usefulness of bisphosphonate treatment by evaluating the effects on LS BMD, annual non-vertebral fracture rate, bone turnover markers and height. This study enabled us to better define the natural history of patients with non-COL1 pathogenic variants. Patients with CRTAP and TMEM38B variants consistently had a prenatal presentation with a short (<3rd p) and bowed femur. Importantly, this prenatal involvement does not predict the postnatal severity of the disease. Regarding treatment by bisphosphonates, all patients showed a significant increase in LS BMD while treated and this increase was dependent on the dose received. The increase in LS BMD also translated in a reduction of fracture rate during treatment. Finally, our study showed that the earlier bisphosphonates are initiated, the greater the fracture rate is reduced. |
Author | Cormier-Daire, Valérie Pejin, Zagorka Brunelle, Perrine Van Gils, Julien Schaefer, Élise Koumakis, Eugénie Pinto, Graziella Michot, Caroline Leheup, Bruno Monnot, Sophie Baujat, Geneviève Charpié, Maëlle |
Author_xml | – sequence: 1 givenname: Maëlle orcidid: 0009-0002-7091-3799 surname: Charpié fullname: Charpié, Maëlle organization: Department of Genomic Medicine for Rare Diseases, French Reference Center for Constitutional Bone Diseases, Necker-Enfants Malades Hospital, Paris Cité University, INSERM UMR 1163, Imagine institute – sequence: 2 givenname: Perrine surname: Brunelle fullname: Brunelle, Perrine organization: Paris Cité University, INSERM UMR 1163, Imagine institute, Institute for Medical Genetics, ULR 7364, Lille University Hospital Jeanne de Flandre Hospital – sequence: 3 givenname: Geneviève surname: Baujat fullname: Baujat, Geneviève organization: Department of Genomic Medicine for Rare Diseases, French Reference Center for Constitutional Bone Diseases, Necker-Enfants Malades Hospital, Paris Cité University, INSERM UMR 1163, Imagine institute – sequence: 4 givenname: Caroline surname: Michot fullname: Michot, Caroline organization: Department of Genomic Medicine for Rare Diseases, French Reference Center for Constitutional Bone Diseases, Necker-Enfants Malades Hospital, Paris Cité University, INSERM UMR 1163, Imagine institute – sequence: 5 givenname: Julien orcidid: 0000-0003-1497-9363 surname: Van Gils fullname: Van Gils, Julien organization: Department of Medical Genetics, University Hospital Centre Bordeaux, University of Bordeaux, INSERM U1211 – sequence: 6 givenname: Bruno surname: Leheup fullname: Leheup, Bruno organization: Department of Clinical Genetics, Nancy Regional University Hospital Center – sequence: 7 givenname: Élise surname: Schaefer fullname: Schaefer, Élise organization: Department of Genomic Medicine for Rare Diseases, Strasbourg University Hospitals – sequence: 8 givenname: Eugénie surname: Koumakis fullname: Koumakis, Eugénie organization: Paris Cité University, INSERM UMR 1163, Imagine institute, Reference Center for Rare Bone Diseases, Rheumatology Institute, Cochin Hospital – sequence: 9 givenname: Zagorka surname: Pejin fullname: Pejin, Zagorka organization: Paris Cité University, INSERM UMR 1163, Imagine institute, Department of Pediatric Orthopedic Surgery, Necker-Enfants Malades Hospital – sequence: 10 givenname: Graziella surname: Pinto fullname: Pinto, Graziella organization: Department of Pediatric Endocrinology, Necker-Enfants Malades Hospital – sequence: 11 givenname: Sophie surname: Monnot fullname: Monnot, Sophie organization: Department of Genomic Medicine for Rare Diseases, French Reference Center for Constitutional Bone Diseases, Necker-Enfants Malades Hospital, Paris Cité University, INSERM UMR 1163, Imagine institute – sequence: 12 givenname: Valérie orcidid: 0000-0002-2839-9856 surname: Cormier-Daire fullname: Cormier-Daire, Valérie email: valerie.cormier-daire@inserm.fr organization: Department of Genomic Medicine for Rare Diseases, French Reference Center for Constitutional Bone Diseases, Necker-Enfants Malades Hospital, Paris Cité University, INSERM UMR 1163, Imagine institute |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38926541$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1rHSEUhqWk5Kv5A1kEoZtupvHbme7KJU0KgWyyF8c5kxpmdKpO4P77eO9NG-iiC1E8z3mP8pyhoxADIHRJyVdKeHudBRWcNoSJhlAlZCM-oFMqtGqk4O1RPRPaNqKl_ASd5fxMSC1qeoxOeNsxJQU9RWkz-eCdnXBewJW0zjiOONkEuK_T8Jjsk5982eLB55gGSBnbMOAEeYkhAy4R9z4vv-JuBVvqTQJbZgjlG7aVKynuo_0L4FzWYfsJfRztlOHibT9Hjz9uHjd3zf3D7c_N9_vGMalK03HhXK_lqKRW3aB65TgorTtnZd8TJwhYTZSmnbJUuh5cKxhj0HGnYBz5OfpyiF1S_L1CLmb22cE02QBxzYYTzVrCBSMV_fwP-hzXFOrjDKc7ghGpKsUOlKs_yglGsyQ_27Q1lJidEHMQYqoQsxdiRG26eote-xmGvy1_DFSAH4BcS-EJ0vvs_8S-ArCKmbc |
Cites_doi | 10.1002/ajmg.a.34269 10.1097/BPO.0b013e318173a923 10.1002/jbmr.3833 10.1002/jbmr.2567 10.1016/S0140-6736(04)16101-1 10.1186/s12887-020-02491-1 10.1515/jpem-2020-0260 10.1002/ajmg.a.35938 10.3389/fgene.2020.00897 10.1002/jbmr.487 10.1016/S0140-6736(13)61091-0 10.1016/j.bone.2005.07.020 10.1002/jbmr.4011 10.1007/s00198-016-3709-1 10.1016/j.cell.2006.08.039 10.1056/NEJMoa063804 10.1111/j.1469-8749.2008.03222.x 10.1159/000369108 10.3346/jkms.2013.28.7.1107 10.1002/jbmr.1480 10.1111/j.1440-1754.2005.00567.x 10.1186/s13023-014-0145-1 10.1002/ajmg.a.35319 10.1007/s00441-009-0872-0 10.1016/j.bone.2016.02.015 10.1016/j.bone.2006.10.010 10.1007/s00198-017-4141-x 10.1136/adc.2003.036590 10.1359/jbmr.2002.17.1.30 10.1016/j.ajhg.2011.01.015 10.1097/00003086-198109000-00015 |
ContentType | Journal Article |
Copyright | The Author(s), under exclusive licence to European Society of Human Genetics 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2024. The Author(s), under exclusive licence to European Society of Human Genetics. |
Copyright_xml | – notice: The Author(s), under exclusive licence to European Society of Human Genetics 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2024. The Author(s), under exclusive licence to European Society of Human Genetics. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 8FD FR3 K9. P64 RC3 7X8 |
DOI | 10.1038/s41431-024-01645-4 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Genetics Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1476-5438 |
EndPage | 1566 |
ExternalDocumentID | 10_1038_s41431_024_01645_4 38926541 |
Genre | Journal Article |
GroupedDBID | --- -Q- 0R~ 29G 2WC 36B 39C 3V. 4.4 406 53G 5GY 70F 7X7 88A 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 AACDK AANZL AASML AATNV AAYOK AAYZH AAZLF ABAKF ABAWZ ABDBF ABJNI ABLJU ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AESKC AEVLU AEXYK AFBBN AFKRA AFSHS AGAYW AGEZK AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ASPBG AVWKF AXYYD AZFZN B0M BAWUL BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 E3Z EAD EAP EAS EBC EBD EBLON EBS EE. EHN EIOEI EJD EMB EMK EMOBN EPL EPT ESX F5P FDQFY FEDTE FERAY FIGPU FIZPM FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HYE HZ~ IWAJR JSO JZLTJ KQ8 LK8 M0L M1P M7P NAO NQJWS O9- OK1 P2P PQQKQ PROAC PSQYO Q2X Q~Q RIG RKO RNS RNT RNTTT ROL RPM SNX SNYQT SOHCF SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TR2 TUS UKHRP Y6R ~8M CGR CUY CVF ECM EIF NPM AAYXX CITATION 8FD FR3 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c256t-934ccb75f65769d6b6c3e6779ca5bb0c40ea7067196a15cbec84222e93c6eff3 |
ISSN | 1018-4813 1476-5438 |
IngestDate | Thu Dec 05 17:44:13 EST 2024 Thu Dec 05 04:47:52 EST 2024 Fri Nov 22 03:12:20 EST 2024 Thu Dec 05 16:36:26 EST 2024 Sat Nov 30 01:18:53 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Language | English |
License | 2024. The Author(s), under exclusive licence to European Society of Human Genetics. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c256t-934ccb75f65769d6b6c3e6779ca5bb0c40ea7067196a15cbec84222e93c6eff3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0009-0002-7091-3799 0000-0003-1497-9363 0000-0002-2839-9856 |
PMID | 38926541 |
PQID | 3134202056 |
PQPubID | 34182 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_3072803420 proquest_journals_3134202056 crossref_primary_10_1038_s41431_024_01645_4 pubmed_primary_38926541 springer_journals_10_1038_s41431_024_01645_4 |
PublicationCentury | 2000 |
PublicationDate | 2024-Dec |
PublicationDateYYYYMMDD | 2024-12-01 |
PublicationDate_xml | – month: 12 year: 2024 text: 2024-Dec |
PublicationDecade | 2020 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: England – name: Leiden |
PublicationTitle | European journal of human genetics : EJHG |
PublicationTitleAbbrev | Eur J Hum Genet |
PublicationTitleAlternate | Eur J Hum Genet |
PublicationYear | 2024 |
Publisher | Springer International Publishing Nature Publishing Group |
Publisher_xml | – sequence: 0 name: Nature Publishing Group – name: Springer International Publishing |
References | Amor, Rauch, Gruenwald, Weis, Eyre, Roughley (CR9) 2011; 155A Homan, Rauch, Grafe, Lietman, Doll, Dawson (CR14) 2011; 26 Caparrós-Martin, Valencia, Pulido, Martínez-Glez, Rueda-Arenas, Amr (CR15) 2013; 161A Bardai, Moffatt, Glorieux, Rauch (CR1) 2016; 27 Glorieux, Ward, Rauch, Lalic, Roughley, Travers (CR11) 2002; 17 Jin, Burrage, Jiang, Lee, Bertin, Chen (CR16) 2018; 2 Venturi, Gandini, Monti, Dalle Carbonare, Corradi (CR13) 2012; 27 Castillo, Samson-Fang (CR2) 2009; 51 Robinson, Trejo, Palomo, Glorieux, Rauch (CR27) 2019; 34 Tang, Wang, Chang, Lee, Tsai, Sun (CR10) 2020; 11 Cho, Ki, Sohn, Kim, Maeng, Jin (CR22) 2013; 28 Shaw, Bishop (CR4) 2005; 90 Fleming, Woodhead, Briody, Hall, Cowell, Ault (CR31) 2005; 41 Tucker, Nelson, Sirrs, Roughley, Glorieux, Moffatt (CR21) 2012; 158A Dubail, Brunelle, Baujat, Huber, Doyard, Michot (CR24) 2020; 35 Mohsenzade, Amirhakimi, Honar, Saki, Omrani, Dabbaghmanesh (CR30) 2021; 21 Minillo, Sobreira, de Faria Soares, de, Jurgens, Ling (CR19) 2014; 5 Marini, Cabral, Barnes (CR8) 2010; 339 Becker, Semler, Gilissen, Li, Bolz, Giunta (CR12) 2011; 88 Zeitlin, Rauch, Travers, Munns, Glorieux (CR32) 2006; 38 Hoyer-Kuhn, Netzer, Koerber, Schoenau, Semler (CR20) 2014; 9 Palomo, Fassier, Ouellet, Sato, Montpetit, Glorieux (CR3) 2015; 30 Bishop, Adami, Ahmed, Antón, Arundel, Burren (CR26) 2013; 382 CR5 Morello, Bertin, Chen, Hicks, Tonachini, Monticone (CR6) 2006; 127 Sakkers, Kok, Engelbert, van Dongen, Jansen, Pruijs (CR25) 2004; 363 Poyrazoglu, Gunoz, Darendeliler, Bas, Tutunculer, Eryilmaz (CR28) 2008; 28 Trejo, Palomo, Montpetit, Fassier, Sato, Glorieux (CR17) 2017; 28 Barnes, Chang, Morello, Cabral, Weis, Eyre (CR7) 2006; 355 Celik, Gonc, Ozon, Alikasifoglu, Rauch, Kandemir (CR18) 2020; 33 Land, Rauch, Travers, Glorieux (CR23) 2007; 40 Lindahl, Kindmark, Rubin, Malmgren, Grigelioniene, Söderhäll (CR29) 2016; 87 IMB Amor (1645_CR9) 2011; 155A G Bardai (1645_CR1) 2016; 27 G Venturi (1645_CR13) 2012; 27 H Castillo (1645_CR2) 2009; 51 K Lindahl (1645_CR29) 2016; 87 R Morello (1645_CR6) 2006; 127 RM Minillo (1645_CR19) 2014; 5 J Dubail (1645_CR24) 2020; 35 N Bishop (1645_CR26) 2013; 382 EP Homan (1645_CR14) 2011; 26 Z Jin (1645_CR16) 2018; 2 T Palomo (1645_CR3) 2015; 30 FH Glorieux (1645_CR11) 2002; 17 J Becker (1645_CR12) 2011; 88 P Trejo (1645_CR17) 2017; 28 S Poyrazoglu (1645_CR28) 2008; 28 SY Cho (1645_CR22) 2013; 28 NJ Shaw (1645_CR4) 2005; 90 H Hoyer-Kuhn (1645_CR20) 2014; 9 JC Marini (1645_CR8) 2010; 339 NB Celik (1645_CR18) 2020; 33 T Tucker (1645_CR21) 2012; 158A 1645_CR5 P Mohsenzade (1645_CR30) 2021; 21 AM Barnes (1645_CR7) 2006; 355 Y-A Tang (1645_CR10) 2020; 11 L Zeitlin (1645_CR32) 2006; 38 C Land (1645_CR23) 2007; 40 JA Caparrós-Martin (1645_CR15) 2013; 161A M-E Robinson (1645_CR27) 2019; 34 F Fleming (1645_CR31) 2005; 41 R Sakkers (1645_CR25) 2004; 363 |
References_xml | – volume: 155A start-page: 2865 year: 2011 end-page: 70 ident: CR9 article-title: Severe osteogenesis imperfecta caused by a small in-frame deletion in CRTAP publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.34269 contributor: fullname: Roughley – volume: 28 start-page: 483 year: 2008 end-page: 7 ident: CR28 article-title: Successful results of Pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards publication-title: J Pediatr Orthop doi: 10.1097/BPO.0b013e318173a923 contributor: fullname: Eryilmaz – volume: 34 start-page: 2198 year: 2019 end-page: 204 ident: CR27 article-title: Osteogenesis imperfecta: skeletal outcomes after bisphosphonate discontinuation at final height publication-title: J Bone Miner Res doi: 10.1002/jbmr.3833 contributor: fullname: Rauch – volume: 30 start-page: 2150 year: 2015 end-page: 7 ident: CR3 article-title: Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years publication-title: J Bone Miner Res doi: 10.1002/jbmr.2567 contributor: fullname: Glorieux – volume: 363 start-page: 1427 year: 2004 end-page: 31 ident: CR25 article-title: Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study publication-title: Lancet doi: 10.1016/S0140-6736(04)16101-1 contributor: fullname: Pruijs – volume: 21 start-page: 37 year: 2021 ident: CR30 article-title: Bone density, fractures and the associated factors in iranian children and adolescent with Osteogenesis Imperfecta publication-title: BMC Pediatr doi: 10.1186/s12887-020-02491-1 contributor: fullname: Dabbaghmanesh – volume: 33 start-page: 1617 year: 2020 end-page: 24 ident: CR18 article-title: Treatment response to long term antiresorptive therapy in osteogenesis imperfecta type VI: does genotype matter? publication-title: J Pediatr Endocrinol Metab doi: 10.1515/jpem-2020-0260 contributor: fullname: Kandemir – volume: 161A start-page: 1354 year: 2013 end-page: 69 ident: CR15 article-title: Clinical and molecular analysis in families with autosomal recessive osteogenesis imperfecta identifies mutations in five genes and suggests genotype-phenotype correlations publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.35938 contributor: fullname: Amr – volume: 11 start-page: 897 year: 2020 ident: CR10 article-title: Novel compound heterozygous mutations in cause rare autosomal recessive osteogenesis imperfecta publication-title: Front Genet doi: 10.3389/fgene.2020.00897 contributor: fullname: Sun – volume: 26 start-page: 2798 year: 2011 end-page: 803 ident: CR14 article-title: Mutations in SERPINF1 cause osteogenesis imperfecta type VI publication-title: J Bone Miner Res doi: 10.1002/jbmr.487 contributor: fullname: Dawson – volume: 382 start-page: 1424 year: 2013 end-page: 32 ident: CR26 article-title: Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(13)61091-0 contributor: fullname: Burren – volume: 38 start-page: 13 year: 2006 end-page: 20 ident: CR32 article-title: The effect of cyclical intravenous Pamidronate in children and adolescents with osteogenesis imperfecta type V publication-title: Bone doi: 10.1016/j.bone.2005.07.020 contributor: fullname: Glorieux – volume: 35 start-page: 1470 year: 2020 end-page: 80 ident: CR24 article-title: Homozygous loss-of-function mutations in CCDC134 are responsible for a severe form of osteogenesis imperfecta publication-title: J Bone Miner Res doi: 10.1002/jbmr.4011 contributor: fullname: Michot – volume: 27 start-page: 3607 year: 2016 end-page: 13 ident: CR1 article-title: DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum publication-title: Osteoporos Int doi: 10.1007/s00198-016-3709-1 contributor: fullname: Rauch – volume: 127 start-page: 291 year: 2006 end-page: 304 ident: CR6 article-title: CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta publication-title: Cell doi: 10.1016/j.cell.2006.08.039 contributor: fullname: Monticone – volume: 355 start-page: 2757 year: 2006 end-page: 64 ident: CR7 article-title: Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta publication-title: N. Engl J Med doi: 10.1056/NEJMoa063804 contributor: fullname: Eyre – volume: 51 start-page: 17 year: 2009 end-page: 29 ident: CR2 article-title: Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review publication-title: Dev Med Child Neurol doi: 10.1111/j.1469-8749.2008.03222.x contributor: fullname: Samson-Fang – volume: 5 start-page: 268 year: 2014 end-page: 75 ident: CR19 article-title: Novel deletion of SERPINF1 causes autosomal recessive osteogenesis imperfecta type VI in two Brazilian families publication-title: Mol Syndromol doi: 10.1159/000369108 contributor: fullname: Ling – volume: 28 start-page: 1107 year: 2013 end-page: 10 ident: CR22 article-title: Osteogenesis imperfecta Type VI with severe bony deformities caused by novel compound heterozygous mutations in SERPINF1 publication-title: J Korean Med Sci doi: 10.3346/jkms.2013.28.7.1107 contributor: fullname: Jin – volume: 27 start-page: 723 year: 2012 end-page: 8 ident: CR13 article-title: Lack of expression of SERPINF1, the gene coding for pigment epithelium-derived factor, causes progressively deforming osteogenesis imperfecta with normal type I collagen publication-title: J Bone Miner Res doi: 10.1002/jbmr.1480 contributor: fullname: Corradi – volume: 41 start-page: 147 year: 2005 end-page: 51 ident: CR31 article-title: Cyclic bisphosphonate therapy in osteogenesis imperfecta type V publication-title: J Paediatr Child Health doi: 10.1111/j.1440-1754.2005.00567.x contributor: fullname: Ault – volume: 9 year: 2014 ident: CR20 article-title: Two years’ experience with denosumab for children with osteogenesis imperfecta Type VI publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-014-0145-1 contributor: fullname: Semler – volume: 158A start-page: 1422 year: 2012 end-page: 6 ident: CR21 article-title: A co-occurrence of osteogenesis imperfecta type VI and cystinosis publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.35319 contributor: fullname: Moffatt – volume: 339 start-page: 59 year: 2010 end-page: 70 ident: CR8 article-title: Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta publication-title: Cell Tissue Res doi: 10.1007/s00441-009-0872-0 contributor: fullname: Barnes – volume: 87 start-page: 11 year: 2016 end-page: 8 ident: CR29 article-title: Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate publication-title: Bone doi: 10.1016/j.bone.2016.02.015 contributor: fullname: Söderhäll – ident: CR5 – volume: 40 start-page: 638 year: 2007 end-page: 44 ident: CR23 article-title: Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous Pamidronate treatment publication-title: Bone doi: 10.1016/j.bone.2006.10.010 contributor: fullname: Glorieux – volume: 28 start-page: 2975 year: 2017 end-page: 83 ident: CR17 article-title: Long-term follow-up in osteogenesis imperfecta type VI publication-title: Osteoporos Int doi: 10.1007/s00198-017-4141-x contributor: fullname: Glorieux – volume: 90 start-page: 494 year: 2005 end-page: 9 ident: CR4 article-title: Bisphosphonate treatment of bone disease publication-title: Arch Dis Child doi: 10.1136/adc.2003.036590 contributor: fullname: Bishop – volume: 17 start-page: 30 year: 2002 end-page: 8 ident: CR11 article-title: Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect publication-title: J Bone Miner Res doi: 10.1359/jbmr.2002.17.1.30 contributor: fullname: Travers – volume: 88 start-page: 362 year: 2011 end-page: 71 ident: CR12 article-title: Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2011.01.015 contributor: fullname: Giunta – volume: 2 start-page: 235 year: 2018 end-page: 9 ident: CR16 article-title: Whole-exome sequencing identifies an intronic cryptic splice site in causing osteogenesis imperfecta type VI publication-title: JBMR contributor: fullname: Chen – ident: 1645_CR5 doi: 10.1097/00003086-198109000-00015 – volume: 33 start-page: 1617 year: 2020 ident: 1645_CR18 publication-title: J Pediatr Endocrinol Metab doi: 10.1515/jpem-2020-0260 contributor: fullname: NB Celik – volume: 51 start-page: 17 year: 2009 ident: 1645_CR2 publication-title: Dev Med Child Neurol doi: 10.1111/j.1469-8749.2008.03222.x contributor: fullname: H Castillo – volume: 41 start-page: 147 year: 2005 ident: 1645_CR31 publication-title: J Paediatr Child Health doi: 10.1111/j.1440-1754.2005.00567.x contributor: fullname: F Fleming – volume: 88 start-page: 362 year: 2011 ident: 1645_CR12 publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2011.01.015 contributor: fullname: J Becker – volume: 27 start-page: 3607 year: 2016 ident: 1645_CR1 publication-title: Osteoporos Int doi: 10.1007/s00198-016-3709-1 contributor: fullname: G Bardai – volume: 26 start-page: 2798 year: 2011 ident: 1645_CR14 publication-title: J Bone Miner Res doi: 10.1002/jbmr.487 contributor: fullname: EP Homan – volume: 28 start-page: 2975 year: 2017 ident: 1645_CR17 publication-title: Osteoporos Int doi: 10.1007/s00198-017-4141-x contributor: fullname: P Trejo – volume: 5 start-page: 268 year: 2014 ident: 1645_CR19 publication-title: Mol Syndromol doi: 10.1159/000369108 contributor: fullname: RM Minillo – volume: 382 start-page: 1424 year: 2013 ident: 1645_CR26 publication-title: Lancet doi: 10.1016/S0140-6736(13)61091-0 contributor: fullname: N Bishop – volume: 11 start-page: 897 year: 2020 ident: 1645_CR10 publication-title: Front Genet doi: 10.3389/fgene.2020.00897 contributor: fullname: Y-A Tang – volume: 34 start-page: 2198 year: 2019 ident: 1645_CR27 publication-title: J Bone Miner Res doi: 10.1002/jbmr.3833 contributor: fullname: M-E Robinson – volume: 155A start-page: 2865 year: 2011 ident: 1645_CR9 publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.34269 contributor: fullname: IMB Amor – volume: 27 start-page: 723 year: 2012 ident: 1645_CR13 publication-title: J Bone Miner Res doi: 10.1002/jbmr.1480 contributor: fullname: G Venturi – volume: 35 start-page: 1470 year: 2020 ident: 1645_CR24 publication-title: J Bone Miner Res doi: 10.1002/jbmr.4011 contributor: fullname: J Dubail – volume: 28 start-page: 1107 year: 2013 ident: 1645_CR22 publication-title: J Korean Med Sci doi: 10.3346/jkms.2013.28.7.1107 contributor: fullname: SY Cho – volume: 158A start-page: 1422 year: 2012 ident: 1645_CR21 publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.35319 contributor: fullname: T Tucker – volume: 30 start-page: 2150 year: 2015 ident: 1645_CR3 publication-title: J Bone Miner Res doi: 10.1002/jbmr.2567 contributor: fullname: T Palomo – volume: 2 start-page: 235 year: 2018 ident: 1645_CR16 publication-title: JBMR contributor: fullname: Z Jin – volume: 38 start-page: 13 year: 2006 ident: 1645_CR32 publication-title: Bone doi: 10.1016/j.bone.2005.07.020 contributor: fullname: L Zeitlin – volume: 28 start-page: 483 year: 2008 ident: 1645_CR28 publication-title: J Pediatr Orthop doi: 10.1097/BPO.0b013e318173a923 contributor: fullname: S Poyrazoglu – volume: 355 start-page: 2757 year: 2006 ident: 1645_CR7 publication-title: N. Engl J Med doi: 10.1056/NEJMoa063804 contributor: fullname: AM Barnes – volume: 90 start-page: 494 year: 2005 ident: 1645_CR4 publication-title: Arch Dis Child doi: 10.1136/adc.2003.036590 contributor: fullname: NJ Shaw – volume: 40 start-page: 638 year: 2007 ident: 1645_CR23 publication-title: Bone doi: 10.1016/j.bone.2006.10.010 contributor: fullname: C Land – volume: 9 year: 2014 ident: 1645_CR20 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-014-0145-1 contributor: fullname: H Hoyer-Kuhn – volume: 127 start-page: 291 year: 2006 ident: 1645_CR6 publication-title: Cell doi: 10.1016/j.cell.2006.08.039 contributor: fullname: R Morello – volume: 339 start-page: 59 year: 2010 ident: 1645_CR8 publication-title: Cell Tissue Res doi: 10.1007/s00441-009-0872-0 contributor: fullname: JC Marini – volume: 17 start-page: 30 year: 2002 ident: 1645_CR11 publication-title: J Bone Miner Res doi: 10.1359/jbmr.2002.17.1.30 contributor: fullname: FH Glorieux – volume: 87 start-page: 11 year: 2016 ident: 1645_CR29 publication-title: Bone doi: 10.1016/j.bone.2016.02.015 contributor: fullname: K Lindahl – volume: 161A start-page: 1354 year: 2013 ident: 1645_CR15 publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.35938 contributor: fullname: JA Caparrós-Martin – volume: 363 start-page: 1427 year: 2004 ident: 1645_CR25 publication-title: Lancet doi: 10.1016/S0140-6736(04)16101-1 contributor: fullname: R Sakkers – volume: 21 start-page: 37 year: 2021 ident: 1645_CR30 publication-title: BMC Pediatr doi: 10.1186/s12887-020-02491-1 contributor: fullname: P Mohsenzade |
SSID | ssj0014771 |
Score | 2.4843533 |
Snippet | Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous group of diseases characterized by brittle bones. Though genetic mutations in
COL1A1... Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous group of diseases characterized by brittle bones. Though genetic mutations in COL1A1... |
SourceID | proquest crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1559 |
SubjectTerms | 59/36 692/308/2056 692/700/1720 Adolescent Adult Bioinformatics Biomedical and Life Sciences Biomedicine Bisphosphonates Bone Density - drug effects Bone Density Conservation Agents - pharmacology Bone Density Conservation Agents - therapeutic use Bone mineral density Bone turnover Child Child, Preschool Collagen (type I) Collagen Type I - genetics Cytogenetics Diphosphonates - therapeutic use Female Femur Fractures Fractures, Bone - genetics Gene Expression Genotypes Human Genetics Humans Male Membrane Proteins - genetics Osteogenesis imperfecta Osteogenesis Imperfecta - drug therapy Osteogenesis Imperfecta - genetics Osteogenesis Imperfecta - pathology Patients Phenotypes Retrospective Studies Spine (lumbar) Vertebrae |
Title | Clinical spectrum of rare bone fragility disorders and response to bisphosphonate treatment: a retrospective study |
URI | https://link.springer.com/article/10.1038/s41431-024-01645-4 https://www.ncbi.nlm.nih.gov/pubmed/38926541 https://www.proquest.com/docview/3134202056 https://www.proquest.com/docview/3072803420 |
Volume | 32 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZKVyAuCJZXYUFG4gZZmsZ5cWuXrcrCVkgUaW-R7dhQtDRVmiDBv-QfMWMnbksLAg6NIjexncwXz3tMyNNBGHAd6sSTOWceyyPmCd_nXp7EqU4FsHiOHt3zaTT5wM4uwotO58dG1FJdiWP5fW9eyf9QFdqArpgl-w-UdZ1CA5wDfeEIFIbjX9H4xKU1Yr5kWX9B0a_EWC5RgPCoS_5xbsTsvKmxaQsylzYu1myaIear5acCfwuQOtdx5zYJulRVWbTJmBulaPeZ8hux1m76B1NWpgA09nN6NnE7eKF7fzm37nmbK2TOR5eXG-79GmNvbPYZFo7c8Pzz-jOvrC1_ASzd3Jt8XcfvzjGlzAWytHc2Vo0B-yVCZGqqmu43xdmFuu-jIdTmsR4r28biyAuZrRbTru5r62ntIrbtWo0O2Q2-j4rsXp5iK8ivGEiWvodTxapkYZObtFXAezJ8n717Nc7evp6-uUIOsDYj65KD4Xg0mjrXFoutFaB9gCaTC0Z5sTvGtrS0owLtuO-NVDS7SW406gwdWmzeIh21OCRX7Qan3w7JtfMmdOM2KVuw0hastNAUwUoRrNSBlTqwUgArbcFKq4Jug5U6sL6knG5BlRqo3iGz8ensZOI1G354EiTvyksDJqWIQx2BFpzmkYhkoKI4TiUPhehL1lc8BvEKuAb3QwnLT4IWTJUGMlJaB3dJdwEzvk-or5XIU6Y08CiWSJXqSAQgKgc8SaWfD3rkWftes6Ut65KZcIwgySwVMqBCZqiQsR45al991nxQqyzwAwbIBQWiR564v2FxRo8bX6iihmv6Zvc3uK5H7lmSueFAUxhEIfN75HlLw3Xnv5_Lgz_P5SG5vv6cjkgXyKkegdhciccNEH8CPeTDBw |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+spectrum+of+rare+bone+fragility+disorders+and+response+to+bisphosphonate+treatment%3A+a+retrospective+study&rft.jtitle=European+journal+of+human+genetics+%3A+EJHG&rft.au=Charpi%C3%A9%2C+Ma%C3%ABlle&rft.au=Brunelle%2C+Perrine&rft.au=Baujat%2C+Genevi%C3%A8ve&rft.au=Michot%2C+Caroline&rft.date=2024-12-01&rft.pub=Nature+Publishing+Group&rft.issn=1018-4813&rft.eissn=1476-5438&rft.volume=32&rft.issue=12&rft.spage=1559&rft.epage=1566&rft_id=info:doi/10.1038%2Fs41431-024-01645-4&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1018-4813&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1018-4813&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1018-4813&client=summon |